Similar studies for GEO DataSets (Select 200066305) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 2000663051.

Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [expression]

(Submitter supplied) The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate as compared to chemotherapy plus either trastuzumab or lapatinib. An extensive biomarker programme was prospectively planned to identify potential predictors of sensitivity to different treatments and evaluate treatment effect on tumor biomarkers. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
88 Samples

Download data: CEL

Series

Accession:: GSE66305

ID:: 200066305

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000663992.

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome variation profiling by SNP array

Platforms:: GPL6801 GPL570
156 Samples

Download data: CEL, CNCHP

Series

Accession:: GSE66399

ID:: 200066399

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000663983.

Organism:: Homo sapiens

Type:: Genome variation profiling by SNP array

Platform:: GPL6801
68 Samples

Download data: CEL, CNCHP, TXT

Series

Accession:: GSE66398

ID:: 200066398

PubMed Full text in PMC Similar studies

Select item 2002345194.

NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

(Submitter supplied) We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
245 Samples

Download data: TXT

Series

Accession:: GSE234519

ID:: 200234519

PubMed Full text in PMC Similar studies

Select item 2001163355.

CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

(Submitter supplied) CALGB 40601 was activated as a 3-arm study (paclitaxel + trastuzumab + lapatinib [THL], paclitaxel + trastuzumab [TH] and paclitaxel + lapatinib [TL]). In December 2010, twoneoadjuvant studies were presented at the Cancer Therapy and Research Center-American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium that affected the scientific and practical enthusiasm for the TL arm. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL11154 GPL16791
265 Samples

Download data: TSV, TXT, XLS

Series

Accession:: GSE116335

ID:: 200116335

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001307886.

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
199 Samples

Download data: TXT

Series

Accession:: GSE130788

ID:: 200130788

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001307877.

(Submitter supplied) Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
89 Samples

Download data: TXT

Series

Accession:: GSE130787

ID:: 200130787

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001307868.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
110 Samples

Download data: TXT

Series

Accession:: GSE130786

ID:: 200130786

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001320559.

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer [RNA-seq]

(Submitter supplied) Despite effective strategies, therapy resistance in HER2+ breast cancer remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Using HER2+ breast cancer parental (P) cell models (AU565, SKBR3, and UACC812), we have established anti-HER2-resistant derivatives made resistant to lapatinib (LR) or lapatinib plus trastuzumab (LTR). more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL11154
15 Samples

Download data: TXT

Series

Accession:: GSE132055

ID:: 200132055

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20004111810.

Mutant PI3K cooperates with HER2 to promote mammary tumor formation and induces trastuzumab resistance in vivo

(Submitter supplied) HER2 (ERBB2) gene amplification and PIK3CA mutations often co-occur in breast cancer, and aberrant activation of the PI3K pathway has been implicated in resistance to HER2-directed therapies. We have created a mouse model of HER2-overexpressing (HER2+), PIK3CAH1047R-mutant breast cancer. Mice expressing both human HER2 and mutant PIK3CA in their mammary glands developed tumors with a significantly shorter latency compared to mice expressing either oncogene alone. more...

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL11383
19 Samples

Download data

Series

Accession:: GSE41118

ID:: 200041118

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20007636011.

03-311 Trastzumab preoperative Trial of Early Stage HER2+ BRCA

(Submitter supplied) Tumor core biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the 03-311 trial. Gene expression profiling was conducted on these tumor biopsies to identify signatures of response to preoperative therapy. This study was initiated to identify biomarkers of response to preoperative trastuzumab-conotaining therapy. We performed transcriptional profiling of patient tumor biopsies obtained at baseline and post brief-exposure to trastuzumab to test the hypothesis that transcriptional changes upon brief-exposure to therapy can provide an early readout of subsequent response.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
100 Samples

Download data: IDAT, TXT

Series

Accession:: GSE76360

ID:: 200076360

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20021687112.

Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.

(Submitter supplied) In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in the PIK3CA, TP53, or E-cadherin genes. Of these co-occurring mutations, HER2 and PIK3CA mutations are the most prevalent gene pair, with approximately 40% of HER2 mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we bred genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids.

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24247
16 Samples

Download data: CSV, TSV

Series

Accession:: GSE216871

ID:: 200216871

PubMed Full text in PMC Similar studies

Select item 20002961613.

Gene expression of primary MMTV-Neu tumors compared to secondary tumors generated from lin- and single tumor initiating cell (TIC) transplantation

(Submitter supplied) Most solid tumors seem to be organized in a hierarchy in which only a fraction of cells, termed tumor-initiating cells (TICs), is capable of disseminating new tumors after transplantation into recipient mice. However, whether a single TIC can induce a tumor or whether it requires additional TICs or non-TICs for tumor initiation is not known. Here we show that injections of single CD24+:Jag1- cells from Her2/Neu+ mammary tumors into recipient mammary glands induced tumors at a frequency of 1/22. more...

Organism:: Mus musculus

Type:: Expression profiling by array

Dataset:: GDS4099
Platform:: GPL6885
16 Samples

Download data: TXT

Series

Accession:: GSE29616

ID:: 200029616

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20002959014.

Expression data from highly purified MMTV-Neu Tumor Initiating Cells (TICs) and the non-TIC CD24- fraction

(Submitter supplied) The cancer stem cell model maintains that tumors are organized in a hierarchy driven by tumor initiating cells (TICs), and that patient survival inversely correlates with TIC gene expression. Here we generated a prognostic signature for HER2+ breast cancer from TICs purified from MMTV-Her2/Neu mammary tumors. TICs from this model, identified as Lin-:CD24+:JAG1- at a frequency of 2-5% by serial and single cell transplantation assays, showed elevated expression of proliferation genes and low expression of differentiation genes (compared to non-TIC fraction CD24- of the same tumor). more...

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL6246
8 Samples

Download data: CEL

Series

Accession:: GSE29590

ID:: 200029590

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 409915.

Human Epidermal Growth Factor Receptor 2-positive breast cancer MMTV-Her2/Neu murine model: primary and secondary mammary tumors

Analysis of primary MMTV-Neu mammary tumors and secondary tumors generated by lin- cell transplantation or by single tumor-initiating cell (TIC) transplantation. Results enable molecular comparisons between the primary and secondary tumors.

Organism:: Mus musculus

Type:: Expression profiling by array, count, 16 specimen, 3 tissue sets

Platform:: GPL6885
Series:: GSE29616
16 Samples

Download data

DataSet

Accession:: GDS4099

ID:: 4099

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 20012263016.

On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

(Submitter supplied) Background: Neoadjuvant chemotherapy is increasingly being used to preoperatively shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes associated with treatment and evaluate whether on-treatment sequential samples can improve response and outcome predictions over diagnostic or excision samples alone. Methods: A total of 95 samples from a cohort of 50 neoadjuvant chemotherapy-treated primary breast cancer patients (aged 29-76, 48% ER+, 20% HER2+) enrolled in the NEO trial taken before, at 2 weeks on-treatment, mid-therapy and at resection were sequenced with Ion Ampliseq transcriptome yielding expression values for 12,635 genes. more...